FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287					
Estimated average burden						
hours per response	: 0.5					

Instruction 1(b	ay continue. See	Fi	d pursuant to Section 16(a) of the Securities Exchange Act of 1934								
	,-		or Section 30(h) of the Investment Company Act of 1940	51	-						
1. Name and Address of Reporting Person [*] <u>YVER ANTOINE</u>			2. Issuer Name and Ticker or Trading Symbol <u>Centessa Pharmaceuticals plc</u> [CNTA] 	5. Relationship of F (Check all applicat Director	10% Owner						
		(Middle) ACEUTICALS PLC ALTRINCHAM	3. Date of Earliest Transaction (Month/Day/Year) 09/01/2022	EVP & Chairman of Development							
(Street) CHESHIRE X0 WA14 2DT (City) (State) (Zip)			4. If Amendment, Date of Original Filed (Month/Day/Year)	Line) X Form filed	nt/Group Filing (Check Ap I by One Reporting Perso I by More than One Repor	n					
(City)	(State)		vative Securities Acquired, Disposed of, or Ben	eficially Owned							
			valive decurriles Acquired, Disposed of, or Den								

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)				Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Ordinary Shares ⁽¹⁾	09/01/2022		S ⁽²⁾		10,423	D	\$4.4121(3)	789,751	D	

											_				
		Ta	ble II - Derivat (e.g., pi					iired, Disp options, d					d		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deriv Secu Acqu (A) o Disp of (D	r osed) r. 3, 4	6. Date Exerc Expiration Da (Month/Day/N	ate	Amou Secu Unde Deriv	rlying ative rity (Instr.	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. The sales reported in this Form 4 represent the number of shares sold by the Reporting Person for the purpose of covering tax withholding obligations in connection with the vesting of the restricted shares pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 17, 2021, as amended, and does not represent a discretionary trade by the Reporting Person.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$4.355 to \$4.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

/s/ Gregory Weinhoff,

attorney-in-fact

09/02/2022

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

erson	Date	